MX2017009698A - Composiciones de inmunoglobulina equina y usos para tratar enfermedades mediadas por filovirus. - Google Patents
Composiciones de inmunoglobulina equina y usos para tratar enfermedades mediadas por filovirus.Info
- Publication number
- MX2017009698A MX2017009698A MX2017009698A MX2017009698A MX2017009698A MX 2017009698 A MX2017009698 A MX 2017009698A MX 2017009698 A MX2017009698 A MX 2017009698A MX 2017009698 A MX2017009698 A MX 2017009698A MX 2017009698 A MX2017009698 A MX 2017009698A
- Authority
- MX
- Mexico
- Prior art keywords
- mediated diseases
- immunoglobulin compositions
- equine immunoglobulin
- compositions
- equine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 241000283073 Equus caballus Species 0.000 title abstract 2
- 241000711950 Filoviridae Species 0.000 title abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 title abstract 2
- 102000018358 immunoglobulin Human genes 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
- C12N2760/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
- C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
Abstract
La descripción proporciona una composición que comprende inmunoglobulina de un equino que se ha hiperinmunizado con un inmunógeno de filovirus. La descripción proporciona, además, métodos para preparar estas composiciones y métodos para usar estas composiciones, por ejemplo, para tratar la infección por virus de Ébola.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562109042P | 2015-01-28 | 2015-01-28 | |
PCT/US2016/015257 WO2016123280A1 (en) | 2015-01-28 | 2016-01-28 | Equine immunoglobulin compositions and uses for treating filovirus-mediated diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017009698A true MX2017009698A (es) | 2018-01-18 |
Family
ID=56544304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017009698A MX2017009698A (es) | 2015-01-28 | 2016-01-28 | Composiciones de inmunoglobulina equina y usos para tratar enfermedades mediadas por filovirus. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20180022790A1 (es) |
EP (1) | EP3226902A4 (es) |
JP (1) | JP2018505185A (es) |
KR (1) | KR20170122750A (es) |
AU (1) | AU2016211475A1 (es) |
BR (1) | BR112017016110A2 (es) |
CA (1) | CA2974114A1 (es) |
IL (1) | IL253672A0 (es) |
MX (1) | MX2017009698A (es) |
SG (1) | SG11201705782QA (es) |
WO (1) | WO2016123280A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3254691A1 (en) * | 2016-06-07 | 2017-12-13 | Abivax | Polyclonal antibodies for use in the prevention and/or treatment of ebola virus disease |
US20190185548A1 (en) * | 2016-06-07 | 2019-06-20 | Abivax | Antiviral polyclonal antibodies against ebola virus and the uses thereof |
CN106868025B (zh) * | 2017-03-13 | 2020-01-21 | 中国人民解放军军事医学科学院生物工程研究所 | 用酵母制备三聚体埃博拉病毒糖蛋白突变体的方法 |
RU2673546C1 (ru) * | 2017-08-10 | 2018-11-28 | Федеральное государственное бюджетное учреждение "48 Центральный научно-исследовательский институт" Министерства обороны Российской Федерации | Способ получения иммуноглобулина против лихорадки эбола из сыворотки крови лошадей, жидкого |
JP2021187810A (ja) * | 2020-06-04 | 2021-12-13 | 東亞合成株式会社 | 抗ウイルス性ペプチドおよびその利用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2776522C (en) * | 2001-10-01 | 2015-02-17 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
US8343495B2 (en) * | 2009-01-10 | 2013-01-01 | Auburn University | Equine antibodies against Bacillus anthracis for passive immunization and treatment |
US9097713B2 (en) * | 2009-09-02 | 2015-08-04 | The United States Of America As Represented By The Secretary Of The Army On Behalf Of Usamrmc | Monoclonal antibodies against glycoprotein of Ebola sudan boniface virus |
KR102351881B1 (ko) * | 2012-04-12 | 2022-01-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법 |
US20180237502A1 (en) * | 2015-03-11 | 2018-08-23 | Integrated Biotherapeutics, Inc. | Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails |
-
2016
- 2016-01-28 JP JP2017540784A patent/JP2018505185A/ja active Pending
- 2016-01-28 AU AU2016211475A patent/AU2016211475A1/en not_active Abandoned
- 2016-01-28 BR BR112017016110A patent/BR112017016110A2/pt not_active Application Discontinuation
- 2016-01-28 KR KR1020177023643A patent/KR20170122750A/ko unknown
- 2016-01-28 MX MX2017009698A patent/MX2017009698A/es unknown
- 2016-01-28 WO PCT/US2016/015257 patent/WO2016123280A1/en active Application Filing
- 2016-01-28 SG SG11201705782QA patent/SG11201705782QA/en unknown
- 2016-01-28 CA CA2974114A patent/CA2974114A1/en not_active Abandoned
- 2016-01-28 EP EP16744072.6A patent/EP3226902A4/en not_active Withdrawn
- 2016-01-28 US US15/547,379 patent/US20180022790A1/en not_active Abandoned
-
2017
- 2017-07-26 IL IL253672A patent/IL253672A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2016211475A1 (en) | 2017-08-10 |
EP3226902A4 (en) | 2019-03-06 |
US20180022790A1 (en) | 2018-01-25 |
IL253672A0 (en) | 2017-09-28 |
KR20170122750A (ko) | 2017-11-06 |
SG11201705782QA (en) | 2017-08-30 |
WO2016123280A1 (en) | 2016-08-04 |
JP2018505185A (ja) | 2018-02-22 |
CA2974114A1 (en) | 2016-08-04 |
EP3226902A1 (en) | 2017-10-11 |
BR112017016110A2 (pt) | 2018-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201991862A1 (ru) | Композиции и способы, предназначенные для лечения гемоглобинопатий | |
PH12018501378A1 (en) | Compositions and methods for the treatment of hemoglobinopathies | |
PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
PH12019501973A1 (en) | Anti-phf-tau antibodies and uses thereof | |
EA030115B9 (ru) | Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
BR112016029318A2 (pt) | tratamento de mielomas | |
MX2022005253A (es) | Anticuerpos neutralizantes de poliomavirus. | |
PH12016501441A1 (en) | Chimeric alkaline phosphate-like proteins | |
MX2016012124A (es) | Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos. | |
IL268160A (en) | Anti-TNF antibodies, preparations and methods for the treatment of active ankylosing spondylitis | |
EA201992232A1 (ru) | Композиции и способы для иммуноонкологии | |
MX2017009698A (es) | Composiciones de inmunoglobulina equina y usos para tratar enfermedades mediadas por filovirus. | |
MX2023004969A (es) | Metodos para tratar y prevenir infeccion por c. difficile. | |
MX2024001617A (es) | Composiciones biofarmaceuticas. | |
EP3512524A4 (en) | METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS | |
EP3500294A4 (en) | ANTI-PD-1 ANTIBODIES OR FRAGMENTS THEREOF FOR TREATING HEPATITIS B | |
MX2023006416A (es) | Anticuerpos, usos y metodos. | |
MY194084A (en) | Interferon beta antibodies and uses thereof | |
EP3681508A4 (en) | METHOD AND COMPOSITION FOR THE TREATMENT OF VIRAL INFECTION | |
MX2018001465A (es) | Nuevos anticuerpos anti-gpvi humana y sus usos. | |
MX2021006865A (es) | Anticuerpos anti-alfa-sinucleina y usos de estos. | |
MX2016009597A (es) | Terapias para el influenzavirus a subtipo h7n9. | |
MX2016009888A (es) | Procedimiento para el tratamiento o la prevencion de condiciones inmunes relacionadas con infecciones utilizando una composicion que comprende igm. | |
MX2022006145A (es) | Anticuerpos trem2 y usos de estos. | |
PH12017501872A1 (en) | Methods of treating diseases |